STERIS stock is down 22% from its 52-week high, and investors are asking whether the healthcare company’s slide reflects a broader problem or just a bad stretch. The Mentor, Ohio-based company has lost ground even as it holds a market-leading position in infection prevention, a strong balance sheet, and a steady stream of strategic acquisitions.
The stock hit a peak of $269.44 on January 16, 2026, and has since slipped below its 50-day and 200-day moving averages. Over the past three months, STE stock has gained 2.1%, underperforming the State Street Health Care Select Sector SPDR ETF (XLV), which has risen 9.7% over the same period. Year-to-date, STE shares have declined 17.1% while the ETF has gained 8.3%. Over the past year, the picture gets worse: STE is down 15.2% versus the ETF’s 22.4% gain.
The Company Behind the Numbers
STERIS plc operates in the healthcare sector with a market capitalization of approximately $20.8 billion. Companies worth between $10 billion and $200 billion are generally classified as “large-cap stocks,” and STERIS fits this description. The company provides consumable products, capital equipment, maintenance and repair services, sterilization solutions, laboratory testing, outsourced reprocessing, and operating room connectivity solutions.
The combination of infection prevention leadership and a broad healthcare product line sets STERIS apart. Its trusted brand, loyal customer base, strong financial position, and strategic acquisitions strengthen its competitive position while supporting continued expansion and innovation.
Why the Slide Matters Now
The gap between STE and the healthcare sector ETF is notable because the company’s business fundamentals look solid on paper. The revenue growth data raises a question about future prospects.
- Revenue growth has slowed to 7.4% annually over the past two years, below the company’s five-year trend.
- Adjusted operating margin has remained broadly unchanged over the past five years.
- Its five-year average ROIC of 5.8% points to relatively modest capital efficiency.
These figures suggest a company that is executing well but not accelerating.
The Technical Picture
Technical traders will note that STE shares have remained below their 50-day and 200-day moving averages since late August and early September, respectively. That signals a recent downtrend, though it does not predict where the stock goes next.
What Investors Are Watching
The question for investors is whether the underperformance is a signal or a noise. The company’s financial position appears strong, but the revenue growth data raises a question about future prospects.
The ROIC figure is worth keeping in mind. A five-year average of 5.8% points to relatively modest capital efficiency, which may have weighed on investor sentiment.
The Bottom Line on STE
STERIS holds a market-leading position, a strong balance sheet, and a steady stream of strategic acquisitions. Yet its stock has underperformed the healthcare sector ETF over the past year, slipping 22% from its 52-week high.
The company’s revenue growth has slowed to 7.4% annually over the past two years, below its five-year trend. Its adjusted operating margin has remained broadly unchanged over the past five years. Its five-year average ROIC of 5.8% points to relatively modest capital efficiency.
These are not fatal numbers, but they are cautionary ones. The stock’s technical picture shows a downtrend, and the gap with the healthcare sector ETF is significant. For investors holding STE, the question is whether the company can accelerate revenue growth or whether the current underperformance is a reflection of slowing revenue growth and limited improvement in profitability.
Key Facts Box
- Market capitalization: approximately $20.8 billion
- 52-week high: $269.44, reached on January 16, 2026
- Three-month performance: +2.1% vs. XLV’s +9.7%
- Year-to-date: -17.1% vs. XLV’s +8.3%
- Past-year performance: -15.2% vs. XLV’s +22.4%
- Revenue growth: 7.4% annually over the past two years, below the five-year trend
- Adjusted operating margin: broadly unchanged over the past five years
- Five-year average ROIC: 5.8%
The stock’s slide is real, and the gap with the healthcare sector ETF is growing. Whether that reflects a problem with STERIS or a problem with the market is a question investors will have to answer for themselves.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.